Testing a new pill for early-to-mid-stage Parkinson's disease
Part of Brain & nervous system clinical trials.
This trial tests a new tablet (VG081821AC) for people with early-to-mid-stage Parkinson's disease who have not recently used levodopa. The goal is to see if it can improve movement symptoms safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have Parkinson's disease that was diagnosed within the last 7 years.
- You have not taken any levodopa-containing medications (like Sinemet or Madopar) in the past 4 weeks, or are willing to stop for 4 weeks.
- Your Parkinson's symptoms are mild to moderate (rated between 1 and 3 on a disease severity scale).
- You do not have serious heart problems, a history of stroke, or uncontrolled high blood pressure.
- You do not have dementia, severe depression, or suicidal thoughts.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, PDR-001, to see if it can safely remove harmful proteins from the brain in people with early Parkinson's disease. It may help slow down the disease.
This trial tests a new oral medication for people with early-onset Parkinson's disease. It aims to see if the drug safely improves motor symptoms and quality of life compared to a placebo.
This early-stage trial tests a new medication called Lu AF28996 in Chinese patients with Parkinson's disease who experience predictable on-off episodes (times when medication works well versus poorly). The study aims to see if this drug can help reduce those difficult off periods.
This trial tests an investigational drug called GT-02287 in people with early-stage Parkinson's disease (diagnosed within the last 7 years). The goal is to see if it is safe and how the body processes it, with a special focus on people with certain genetic changes (GBA1 mutations) that may be linked to Parkinson's.
This study tests an investigational drug to see if it can help people with early Parkinson's disease. It may offer a new treatment option to manage symptoms.
This trial tests an experimental oral drug called GT-02287 for people with early-stage Parkinson's disease. The study aims to see if the drug can slow progression by targeting a protein linked to Parkinson's, and participants must be willing to have genetic testing and a spinal tap to check for that protein marker.
Hear when a new Parkinson Disease (PD) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.